Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Will ISIS Pharmaceuticals, Inc. (ISIS) Right Pfizer Inc. (PFE)’s Wrong?

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) started the year strong with a Food and Drug Administration approval for genetic high cholesterol drug Kynamro. As Kynamro prepares for launch, Isis’ active pipeline continues to push forward. Today, the antisense drug developer announced the initiation of phase 2/3 trials for ISIS-TTRRx, which treats a rare neurodegenerative disease called transthyretin amyloidosis.

This GlaxoSmithKline plc (ADR) (NYSE:GSK) partnered drug looks strong going into mid-stage. But the companies need to avoid making the same mistake that sent Pfizer Inc. (NYSE:PFE)‘s similar product back for another clinical trial.

ISIS Pharmaceuticals, Inc.Market potential
ISIS-TTRRx treats transthyretin, or TTR, amyloidosis — a genetic condition caused by protein buildups that disrupt the function of tissue and organs. TTR amyloidosis has three main types defined by what body system the proteins affect. ISIS-TTRRX targets the types affecting the peripheral nervous system and/or the heart.

TTR amyloidosis can lead to limb numbness, quick drops in blood pressure, and an enlarged heart. Late stages can cause potentially fatal damage to the heart and kidneys. Kidney transplants are the only currently available treatment in the United States.

The disease is rare, but orphan drugs tend to price high enough to compensate. Research firm Global Data estimates that the general amyloidosis market will reach $2.58 billion by 2019, up from $1.43 billion last year. Isis’ drug will belong to a subsection of that market if it receives FDA approval.

Will ISIS-TTRRx make it that far?

Chance of approval?
It’s tough to judge a drug’s approval chances this early in the pipeline. Isis did report positive phase 1 data early last year, and the FDA granted Fast Track designation in December. But Isis and Glaxo need to make sure that the late-stage trials clearly demonstrate efficacy if they don’t want to run into the same problem as Pfizer.

Pfizer’s Vyndaqel became the first EU-approved treatment for the peripheral nervous system form. But the drug didn’t fare as well in front of the FDA. Pfizer received a complete response letter requesting another trial that better demonstrates Vyndaqel’s efficacy.

Deal financials
The phase 2/3 initiation for ISIS-TTRRx triggered a $7.5 million payment from GlaxoSmithKline.

Isis and Glaxo recently amended their agreement due to the drug’s sped-up review process. Isis awaits the other half of a $20 million upfront payment plus an additional $2.5 million defined in the new deal. The freshly triggered milestone payment will lead to further pre-licensing milestones up to $50 million. Isis will receive double-digit royalties on sales if the drug makes it to market.

The article Will Isis Right Pfizer’s Wrong? originally appeared on and is written by Brandy Betz.

Fool contributor Brandy Betz has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!